Kartos Therapeutics

Kartos Therapeutics is a private, clinical-stage biotech advancing navtemadlin, a potent and selective oral MDM2 inhibitor, for cancers with wild-type TP53. The company's lead program is in advanced clinical development for myelofibrosis, with additional studies in acute myeloid leukemia and Merkel cell carcinoma. Kartos's strategy centers on leveraging deep biological insight into the MDM2-p53 pathway to induce apoptosis in cancer cells, targeting significant unmet needs in both hematologic malignancies and solid tumors.

Specialized expertise in small molecule inhibition of the MDM2-p53 interaction to restore tumor suppressor function and induce apoptosis in wild-type TP53 cancers.

The MDM2 inhibitor space has seen several entrants (e.g., idasanutlin, milademetan) with mixed success, indicating a high bar for efficacy and tolerability. In myelofibrosis, navtemadlin competes with next-generation JAK inhibitors, BET inhibitors, and other novel mechanisms, making differentiation critical.